{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:50:17Z","timestamp":1793299817540,"version":"4.5.0"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2022,4,27]]},"abstract":"<jats:p>Cefiderocol is the first siderophore-conjugated cephalosporin approved for use in the treatment of human bacterial infections. Cefiderocol has broad-spectrum Gram-negative activity against difficult-to-treat bacterial pathogens that can cause serious infections.<\/jats:p>","DOI":"10.1128\/spectrum.02712-21","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T11:00:31Z","timestamp":1646823631000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":102,"title":["<i>In Vitro<\/i>\n                    Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program"],"prefix":"10.1128","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-5216","authenticated-orcid":true,"given":"Dee","family":"Shortridge","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8419-6308","authenticated-orcid":true,"given":"Jennifer M.","family":"Streit","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8648-1137","authenticated-orcid":true,"given":"Rodrigo","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1782","authenticated-orcid":true,"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Global antimicrobial resistance and use surveillance system (GLASS) report","author":"WHO","year":"2021","unstructured":"WHO. 2021. Global antimicrobial resistance and use surveillance system (GLASS) report. WHO, Geneva, Switzerland."},{"key":"e_1_3_3_3_2","volume-title":"Antibiotic resistance threats in the United States, 2019 (2019 AR threats report)","author":"CDC","year":"2019","unstructured":"CDC. 2019. Antibiotic resistance threats in the United States, 2019 (2019 AR threats report). CDC, Atlanta, GA."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy347"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy293"},{"key":"e_1_3_3_6_2","volume-title":"Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline","author":"WHO","year":"2019","unstructured":"WHO. 2019. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline. WHO, Geneva, Switzerland."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01968-17"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz827"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01454-17"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky482"},{"key":"e_1_3_3_11_2","unstructured":"European Medicines Agency. 2020. Fetcroja (cefiderocol) summary of product characteristics. European Medicines Agency Amsterdam the Netherlands. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fetcroja-epar-product-information_en.pdf."},{"key":"e_1_3_3_12_2","unstructured":"FDA. 2019. Fetroja (cefiderocol) prescribing information. FDA Silver Spring MD. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209445s000lbl.pdf."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00797-20"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz826"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.07.027"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2019.0298"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa121"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy346"},{"key":"e_1_3_3_19_2","volume-title":"Performance standards for antimicrobial susceptibility testing, M100","author":"Clinical and Laboratory Standards Institute","year":"2021","unstructured":"Clinical and Laboratory Standards Institute. 2021. Performance standards for antimicrobial susceptibility testing, M100, 31st ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"31"},{"key":"e_1_3_3_20_2","volume-title":"Routine and extended internal quality control for MIC determination and disk diffusion as recommended by The European Committee on Antimicrobial Susceptibility Testing","author":"EUCAST","year":"2021","unstructured":"EUCAST. 2021. Routine and extended internal quality control for MIC determination and disk diffusion as recommended by The European Committee on Antimicrobial Susceptibility Testing, 11.0 ed.","edition":"11"},{"key":"e_1_3_3_21_2","volume-title":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters","author":"EUCAST","year":"2021","unstructured":"EUCAST. 2021. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, 11.0 ed.","edition":"11"},{"key":"e_1_3_3_22_2","unstructured":"FDA. 2021. FDA-recognized antimicrobial susceptibility test interpretive criteria. FDA Silver Spring MD. https:\/\/www.fda.gov\/drugs\/development-resources\/fda-recognized-antimicrobial-susceptibility-test-interpretive-criteria. Accessed August 17 2020."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.02712-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.02712-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T09:45:10Z","timestamp":1651052710000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.02712-21"}},"subtitle":[],"editor":[{"given":"Nilton","family":"Lincopan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4,27]]}},"alternative-id":["10.1128\/spectrum.02712-21"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.02712-21","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"2021-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02712-21"}}